Compositions and methods for short interfering nucleic acid inhibition of Na
View Patent ↗The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Na v 1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.
1. An isolated or recombinant short interfering nucleic acid comprising the nucleotide sequence of SEQ ID NO: 3, or an analogue thereof.
2. The isolated or recombinant short interfering nucleic acid of claim 1 comprising the nucleotide sequence of SEQ ID NO: 3.
3. The isolated or recombinant short interfering nucleic acid of claim 2 , further comprising a 3′ overhang.
4. The isolated or recombinant short interfering nucleic acid of claim 2 , further comprising a complementary nucleotide sequence to SEQ ID NO: 3.
5. The isolated or recombinant short interfering nucleic acid of claim 4 , wherein the complementary nucleotide sequence further comprises a 3′ overhang.
6. A pharmaceutical composition comprising a short interfering nucleic acid and a pharmaceutically acceptable carrier, wherein the short interfering nucleic acid comprises SEQ ID NO: 3or an analogue thereof.
7. The pharmaceutical composition of claim 6 , wherein the short interfering nucleic acid comprises SEQ ID NO: 3.
8. The pharmaceutical composition of claim 7 , wherein the short interfering nucleic acid further comprises a 3′ overhang.
9. The pharmaceutical composition of claim 6 , wherein the short interfering nucleic acid further comprises a complementary nucleotide sequence to SEQ ID NO: 3.
10. The pharmaceutical composition of claim 6 , wherein the complementary nucleotide sequence further comprises a 3′ overhang.
11. An isolated or recombinant short interfering nucleic acid comprising a nucleotide sequence and a complementary nucleotide sequence thereto, wherein the nucleotide sequence is SEQ ID NO: 3.
12. The isolated or recombinant short interfering nucleic acid of claim 11 , wherein the nucleotide sequence further comprises a 3′ overhang and the complementary nucleotide sequence further comprises a 3′ overhang.
13. A pharmaceutical composition comprising a short interfering nucleic acid and a pharmaceutically acceptable carrier, wherein the short interfering nucleic acid comprises a nucleotide sequence and a complementary nucleotide sequence thereto, wherein the nucleotide sequence is SEQ ID NO: 3.
14. The pharmaceutical composition of claim 13 , wherein the nucleotide sequence further comprises a 3° overhang and the complementary nucleotide sequence further comprises a 3′ overhang.